Interaction with damaged vessel wall in vivo in humans induces platelets to express CD40L resulting in endothelial activation with no effect of aspirin intake.

Activated platelets express CD40L on their plasma membrane and release the soluble fragment sCD40L. The interaction between platelet surface CD40L and endothelial cell CD40 leads to the activation of endothelium contributing to atherothrombosis. Few studies have directly demonstrated an increased expression of platelet CD40L in conditions of in vivo platelet activation in humans, and no data are available on its relevance for endothelial activation. We aimed to assess whether platelets activated in vivo at a localized site of vascular injury in humans express CD40L and release sCD40L, whether the level of platelet CD40L expression attained in vivo is sufficient to induce endothelial activation, and whether platelet CD40L expression is inhibited by aspirin intake. We used the skin-bleeding-time test as a model to study the interaction between platelets and a damaged vessel wall by measuring CD40L in the blood emerging from a skin wound in vivo in healthy volunteers. In some experiments, shed blood was analyzed before and 1 h after the intake of 500 mg of aspirin. Platelets from the bleeding-time blood express CD40L and release soluble sCD40L, in a time-dependent way. In vivo platelet CD40L expression was mild but sufficient to induce VCAM-1 expression and IL-8 secretion in coincubation experiments with cultured human endothelial cells. Moreover, platelets recovered from the bleeding-time blood activated endothelial cells; an anti-CD40L antibody blocked this effect. On the contrary, the amount of sCD40L released by activated platelets at a localized site of vascular injury did not reach the concentrations required to induce endothelial cell activation. Soluble monocyte chemoattractant protein-1, a marker of endothelium activation, was increased in shed blood and correlated with platelet CD40L expression. Aspirin intake did not inhibit CD40L expression by platelets in vivo. We concluded that CD40L expressed by platelets in vivo in humans upon contact with a damaged vessel wall activates endothelium; aspirin treatment does not inhibit this mechanism.

[1]  R. Kroczek,et al.  The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. , 2001, Blood.

[2]  W. Daniel,et al.  Upregulation of CD40 and CD40 Ligand (CD154) in Patients With Moderate Hypercholesterolemia , 2001, Circulation.

[3]  P. Lucidi,et al.  Hyperglycemia-Induced Platelet Activation in Type 2 Diabetes Is Resistant to Aspirin but Not to a Nitric Oxide–Donating Agent , 2010, Diabetes Care.

[4]  L. Jennings,et al.  Regulation of CD40L (CD154) and CD62P (p-selectin) surface expression upon GPIIb-IIIa blockade of platelets from stable coronary artery disease patients. , 2010, Thrombosis research.

[5]  A. Michelson,et al.  Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine diphosphate, or an in vivo wound. , 1991, Blood.

[6]  K. Mann,et al.  Simvastatin Depresses Blood Clotting by Inhibiting Activation of Prothrombin, Factor V, and Factor XIII and by Enhancing Factor Va Inactivation , 2001, Circulation.

[7]  W. Kuliczkowski,et al.  Aspirin failure course during exercise and its connection with soluble CD40L. , 2007, Thrombosis research.

[8]  P. Gresele,et al.  Leukotriene B4 production by stimulated whole blood: comparative studies with isolated polymorphonuclear cells. , 1986, Biochemical and biophysical research communications.

[9]  J. Freedman,et al.  Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. , 2005, The American journal of cardiology.

[10]  Y. Merhi,et al.  Enhanced Levels of Soluble CD40 Ligand Exacerbate Platelet Aggregation and Thrombus Formation Through a CD40-Dependent Tumor Necrosis Factor Receptor–Associated Factor-2/Rac1/p38 Mitogen-Activated Protein Kinase Signaling Pathway* , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[11]  M. Gawaz,et al.  Engagement of Glycoprotein IIb/IIIa (&agr;IIb&bgr;3) on Platelets Upregulates CD40L and Triggers CD40L-Dependent Matrix Degradation by Endothelial Cells , 2002, Circulation.

[12]  F. Santilli,et al.  Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus , 2010, Journal of thrombosis and haemostasis : JTH.

[13]  R. Kroczek,et al.  Activated Platelets Induce Tissue Factor Expression on Human Umbilical Vein Endothelial Cells by Ligation of CD40 , 1998, Thrombosis and Haemostasis.

[14]  W. Koenig,et al.  Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease , 2003, Circulation.

[15]  J. J. Varo,et al.  Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in the metabolic syndrome. , 2010, American journal of physiology. Endocrinology and metabolism.

[16]  J. Sampol,et al.  Reevaluation of Trypsin-EDTA for Endothelial Cell Detachment before Flow Cytometry Analysis , 1996 .

[17]  Patrick André,et al.  Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. , 2002, Circulation.

[18]  Reinhold Förster,et al.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.

[19]  G. Stel,et al.  A new model of human aortic endothelial cells in vitro. , 2000, Biochimie.

[20]  A. Michelson,et al.  vivo wound (see comments) whole blood stimulated by thrombin, adenosine diphosphate, or an in Downregulation of the platelet surface glycoprotein Ib-IX complex in , 2011 .

[21]  J. Manson,et al.  Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study , 1992, The Lancet.

[22]  J. Westwick,et al.  Investigation of the Interaction of Blood Platelets with the Coagulation System at the Site of Plug Formation In Vivo in Man - Effect of Low-Dose Aspirin , 1987, Thrombosis and Haemostasis.

[23]  D. Phillips,et al.  Inhibitory Effects of Glycoprotein IIb/IIIa Antagonists and Aspirin on the Release of Soluble CD40 Ligand During Platelet Stimulation , 2003, Circulation.

[24]  F. Santilli,et al.  Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control , 2005, Diabetologia.

[25]  AlbertSchömig,et al.  Activated Platelets Induce Monocyte Chemotactic Protein-1 Secretion and Surface Expression of Intercellular Adhesion Molecule-1 on Endothelial Cells , 1998 .

[26]  Semple,et al.  Preanalytical requirements for flow cytometric evaluation of platelet activation: choice of anticoagulant , 1999, Transfusion medicine.

[27]  C. Patrono,et al.  Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. , 1980, Thrombosis research.

[28]  M. Wolzt,et al.  Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[29]  P. Gresele,et al.  Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. , 1987, The Journal of clinical investigation.

[30]  N. Kleiman,et al.  Soluble CD40 ligand in acute coronary syndromes. , 2003, The New England journal of medicine.

[31]  E. Ongini,et al.  A novel nitric oxide‐releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression 1 , 2005, Journal of thrombosis and haemostasis : JTH.

[32]  A. Orlacchio,et al.  Platelets Release their Lysosomal Content In Vivo in Humans upon Activation , 2000, Thrombosis and Haemostasis.

[33]  G. Davı̀,et al.  , Hypercholesterolemia : Effects of Statin Therapy Association Between Enhanced Soluble CD 40 L and Prothrombotic State in , 2002 .

[34]  F. Cipollone,et al.  Preprocedural Level of Soluble CD40L Is Predictive of Enhanced Inflammatory Response and Restenosis After Coronary Angioplasty , 2003, Circulation.

[35]  S. Fiorucci,et al.  Salicylates inhibit adhesion and transmigration of T lymphocytes by preventing integrin activation induced by contact with endothelial cells. , 1998, Blood.

[36]  H. Weiss,et al.  Studies of thromboxane B2, platelet factor 4, and fibrinopeptide A in bleeding-time blood of patients deficient in von Willebrand factor, platelet glycoproteins Ib and IIb-IIIa, and storage granules. , 1993, Blood.

[37]  A. Becker,et al.  CD40 ligand is selectively expressed on CD4+ T cells and platelets: implications for CD40–CD40L signalling in atherosclerosis , 2003, The Journal of pathology.

[38]  D. Phillips,et al.  Soluble CD40 ligand induces β3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .

[40]  D. Francisci,et al.  HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction , 2009, AIDS.

[41]  F. Santilli,et al.  Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment , 2010, Journal of thrombosis and haemostasis : JTH.

[42]  F. Sánchez-Jiménez,et al.  Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. , 2009, The international journal of biochemistry & cell biology.

[43]  D. Simon,et al.  GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention , 2004, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[44]  P. Gresele,et al.  Platelets release active matrix metalloproteinase‐2 in vivo in humans at a site of vascular injury: lack of inhibition by aspirin , 2007, British journal of haematology.

[45]  K. Schrör,et al.  Platelet CD40 ligand (CD40L) – subcellular localization, regulation of expression, and inhibition by clopidogrel , 2001, Platelets.

[46]  N. Bayley,et al.  Failure , 1890, The Hospital.

[47]  H. Gold,et al.  Cardiopulmonary Bypass Induces Release of Soluble CD40 Ligand , 2002, Circulation.

[48]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[49]  W. Daniel,et al.  Platelets contribute to enhanced MCP-1 levels in patients with chronic heart failure , 2007, Heart.

[50]  R. Hynes,et al.  CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism , 2002, Nature Medicine.